Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
Novo Nordisk shares dive after heart medicine fails trial
The reporting (7)
- Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail Fierce Biotech · 7h ago
- Novo Nordisk inflammation-targeting drug misses mark in heart disease study STAT · 7h ago
- Novo hit by failure of key pipeline hopeful ziltivekimab in CV outcomes study FirstWord Pharma · 7h ago
- Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation Yahoo Finance · 7h ago
- Novo drug fails to reduce cardiovascular risk in late-stage trial, shares slide Reuters · 7h ago
- Novo Nordisk Shares Drop After Drug Candidate Fails in Trial WSJ · 7h ago
- Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline CNBC · 7h ago
The story so far
Novo Nordisk's shares have taken a hit. The decline comes as the company's heart medicine failed a trial.
The failure is a result of the company's inflammation-targeting drug missing its mark in a heart disease study. According to Yahoo Finance, the update was provided on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation.
FirstWord Pharma notes that the failure is of key pipeline hopeful ziltivekimab in a CV outcomes study. The question now is what this means for Novo Nordisk's pipeline going forward
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. Updated 1h ago.
The obvious questions
What happened to Novo Nordisk's shares?
Novo Nordisk's shares dove after its heart medicine failed a trial
What drug failed the trial?
The inflammation-targeting drug ziltivekimab failed the trial
What was the trial for?
The trial was for a heart disease study
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Sanofi’s new CEO Garijo outlines an R&D restructuring and expansion plan as the company balances strong second-quarter earnings against investor concerns.
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Medical professionals are reevaluating obesity treatment protocols as GLP-1 usage rises and questions emerge regarding long-term dependency and patient age limits.
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK launches a $2.5 billion, three‑year savings drive to speed late‑stage trials and shift its research hub to Arizona.
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
Otsuka’s newly approved ADHD drug Simtriyo opens a $615 million market and signals the company’s next big CNS push.
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
AstraZeneca stock gains as strong performance in cancer medicine portfolios bolsters investor confidence and keeps long-term revenue targets on track.
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
A new FDA‑approved drug gives ADHD patients of all ages a first‑in‑class treatment option.